What is the primary target of the monoclonal antibody Ipilimumab in cancer immunotherapy?
Show answer and explanation
Correct answer: CTLA-4
Ipilimumab is a checkpoint inhibitor that blocks CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4). Blocking this 'brake' on the immune system allows for enhanced T-cell activation and attack against cancer cells.
Keep practicing
More Monoclonal Antibodies questions
- Tocilizumab is a monoclonal antibody that blocks the receptor for which pro-inflammatory cytokine?
- Which mechanism describes how many monoclonal antibodies, such as Rituximab, induce the destruction of target cells via NK cells?
- Basiliximab is used in organ transplantation to prevent acute rejection by targeting which molecule?
- The 'mab' suffix in pharmacologic nomenclature stands for:
- Which monoclonal antibody is a PCSK9 inhibitor used to treat familial hypercholesterolemia?
- What does the 'xi' in the name of the monoclonal antibody Rituximab indicate about its structure?